Rosetta s Q1 Revenues Up Sharply with Licensing Deals; Losses Narrower than Expected | GenomeWeb

NEW YORK, April 19  - Rosetta Inpharmatics reported $4.7 million in revenues for the first quarter of 2001 Thursday, up from $548,000 for the first quarter of 2000, while losses were narrower than Wall Street's expectations.

The Kirkland, Wash., bioinformatics company attributed the revenue surge to a collaboration with Monsanto in crop gene expression that the companies initiated at the end of November 2000, and to sales of the Rosetta Resolver system. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.